A US-based KOL discusses current treatment options in ovarian cancer and the need for therapies in the treatment of platinum-resistant disease. Novel ADCs and immunotherapies in the pipeline are also discussed, in addition to treatment options in low-grade serous ovarian cancer, a critical area of unmet need.

This interview was conducted on April 22, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.